Naltrexone


Curated chemical-phenotype interactions from CTD
GO IDGO nameInteraction typeReference
GO:0000278 Mitotic cell cycle Increases phenotype PMID:2243594
GO:0002027 Regulation of heart rate Affects phenotype PMID:10812285; PMID:15917999; PMID:16023251
GO:0006915 Apoptotic process Decreases phenotype PMID:15694688
GO:0008217 Regulation of blood pressure Affects phenotype PMID:12957222; PMID:15917999; PMID:16023251
GO:0008219 Cell death Increases phenotype PMID:27323860
GO:0008283 Cell population proliferation Increases phenotype PMID:2243594
GO:0030154 Cell differentiation Increases phenotype PMID:8384517
GO:0030182 Neuron differentiation Affects phenotype PMID:26877219
GO:0035810 Positive regulation of urine volume Increases phenotype PMID:17909753
GO:0042310 Vasoconstriction Increases phenotype PMID:11448484; PMID:15917999
GO:0042311 Vasodilation Increases phenotype PMID:11448484; PMID:15917999
GO:0048149 Behavioral response to ethanol Decreases phenotype PMID:29859012
GO:0070994 Detection of oxidative stress Increases phenotype PMID:24486436
GO:0072672 Neutrophil extravasation Increases phenotype PMID:15917999
GO:1990770 Small intestine smooth muscle contraction Increases phenotype PMID:37245850
DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.